Virus Shell Nanoparticles Vaccinate Cancers in Mice

virus-shell-nanoparticlesThe magazine Science hailed cancer immunotherapy as the breakthrough of the year two years ago, and the field has been gaining traction since. The idea is to activate the body’s own immune cells to recognize cancer cells as disease-causing, and to train them to attack the cancer. Effectively, instead of delivering toxic chemotherapeutics to the whole body, cancer immunotherapy would allow strategic targeting using the body’s immune cells only. It’s kind of like a vaccine, but for cancer. Many approaches are now in clinical trials to explore this avenue, and are showing much potential.

A new study from the Fiering Lab at Dartmouth’s School of Medicine used an empty cowpea mosaic virus as an adjuvant for stimulating the immune system. (That sore arm you get after a flu shot? That’s your immune system jumping into action.) These viruses lack their core DNA like many vaccines, so are non-infectious, but have surfaces that can be recognized by the immune system.

READ THE REST HERE

About Peter Coffaro 1094 Articles
A growth-driven and strategic executive, Peter Coffaro commands more than 20 years of progressive management success within the medical device industry. As a District Sales Manager for Stryker Orthopaedics, Peter was responsible for managing and directing a regional sales force to achieve sales and profit goals within the Rocky Mountain region. Previously, he was the Director of Sales & Marketing for Amp Orthopedics. In this role, Peter was responsible for planning, developing, and leading all sales and marketing initiatives. Peter is a former orthopedic distributor in the Pacific Northwest. He has also worked with DePuy Orthopaedics as well as Zimmer, and held positions in sales, sales training, and sales management. Peter has an extensive background in organizational development, business development, sales management, negotiating and P&L management. Peter holds a B.S. degree in Biology from Northern Illinois University.

Be the first to comment

Leave a Reply

Your email address will not be published.


*